Trial
NCT05011513
Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Pfizer
Collaborators
—
Condition
COVID-19
Intervention
PF-07321332
Why stopped
Enrollment ceased due to a very low rate of hospitalization or death observed in the standard-risk patient population
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-08-14